Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. PYXS
PYXS logo

PYXS

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

PYXS News

Pyxis Oncology Reports Expanded Losses and Milestones for MICVO

Mar 23 2026NASDAQ.COM

PYXIS ONCOLOGY INC ANTICIPATES FUNDING TO LAST THROUGH Q4 2026

Mar 23 2026moomoo

Pyxis Oncology Reports Q4 Earnings Miss with Revenue Decline

Mar 23 2026seekingalpha

PYXIS ONCOLOGY RELEASES BUSINESS UPDATE ALONG WITH FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Mar 23 2026moomoo

PYXIS ONCOLOGY Reports FY EPS of USD -1.28

Mar 23 2026moomoo

Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology

Jan 12 2026Newsfilter

ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept

Jan 08 2026NASDAQ.COM

Experts Raise Concerns About Pyxis Oncology's Small Clinical Trial

Dec 19 2025Benzinga

Tesla's Price Target of $444? Check Out 10 Leading Analyst Predictions for Friday

Dec 19 2025Benzinga

Nasdaq Rises More Than 200 Points as US Inflation Decreases to 2.7%

Dec 18 2025Benzinga

Dow Rises 400 Points as Accenture Reports Stronger-Than-Expected Earnings

Dec 18 2025Benzinga

Pyxis Oncology Reports 46% ORR for MICVO Monotherapy in R/M HNSCC

Dec 18 2025Globenewswire

Pyxis Oncology Reports 46% ORR for MICVO Monotherapy in R/M HNSCC

Dec 18 2025Newsfilter

Pyxis Shares Drop After Phase 1 Results for Head and Neck Cancer Treatment Candidate

Dec 18 2025SeekingAlpha

Pyxis Oncology to Showcase Translational Data and Important Biological Insights on MICVO's Mechanism of Action at Upcoming Medical Conferences

Oct 13 2025Newsfilter

Pyxis Oncology Names Alex Kane as Senior Vice President of Investor Relations and Capital Markets

Oct 09 2025Newsfilter